As new therapies move through clinical trials, the management of uveal melanoma is entering a period of significant change. In this episode of Cancer Advances, Arun Singh, MD, discusses emerging strategies to avoid radiation, prevent radiation-related vision loss and shrink tumors before definitive treatment. Learn how these innovations address longstanding unmet needs and reshape care for patients with this rare ocular malignancy.

How can oncologists initiate meaningful goals-of-care discussions earlier in the disease course? In this episode, Dr. Natalie Jacobowski outlines practical communication strategies, including language, timing and approaches to reduce stigma and align care with patient values. She emphasizes how early, transparent dialogue, and framing concerns as shared worries, can enhance decision-making across the cancer continuum, including for younger patients.

How can better data improve decision-making in a curable but nuanced disease like testicular cancer? This episode explores how large language models can turn unstructured clinical notes into actionable insights, helping clinicians refine treatment selection, understand practice variation and balance cure with long-term toxicity management.

Is there a role for earlier integration of lutetium PSMA therapy in mCRPC management? Emerging evidence supports its use in the pre-taxane setting, prompting a shift in sequencing decisions. This episode outlines patient selection, PSMA imaging requirements and how to balance disease aggressiveness, tolerability and real-world considerations when choosing between lutetium and chemotherapy.

As cancer care becomes increasingly personalized, treatment deescalation is emerging as a key strategy to balance efficacy with quality of life. In this episode of Cancer Advances, Jame Abraham, MD, Enterprise Chair of Hematology and Medical Oncology at Cleveland Clinic, discusses how clinicians are rethinking dose intensity, duration and therapeutic selection across disease settings. Learn how evolving evidence, patient preferences and emerging technologies like AI are shaping treatment decisions and redefining standards of care.

How can we better predict progression and outcomes in a disease where treatment decisions must be made in days, sometimes hours? In this episode of Cancer Advances, Moaath Mustafa Ali, MD, MPH, discusses emerging longitudinal and evolutionary modeling approaches that integrate clinical, genomic and treatment data over time to improve risk stratification in acute myeloid leukemia. Learn how these models may support earlier, more informed decisions around therapy selection, relapse risk and long-term management.

Young patients requiring pelvic radiation face limited fertility preservation options. In this episode of Cancer Advances, Robert DeBernardo, MD, and Johanna Kelley, MD, both gynecologic oncologists at Cleveland Clinic, discuss uterine transposition—a novel surgical approach that protects both ovarian function and the uterus—using a real world rectal cancer case. Learn which patients may benefit, how the multidisciplinary model works and what this technique could mean for counseling, referrals and long term reproductive outcomes.

Shilpa Gupta, MD, Genitourinary Medical Oncologist, joins the Cancer Advances podcast to explore how perioperative immunotherapy and ctDNA are redefining management of muscle-invasive bladder cancer. She reviews emerging phase III data and explains how it can inform treatment selection, referral timing and adjuvant decision making in clinical practice.

Lilyana Angelov, MD, Neurosurgeon and Director of the Cleveland Clinic Gamma Knife Center, Samuel Chao, MD, Radiation Oncologist and Associate Director of the Gamma Knife Center; and Ajit Krishnaney, MD, Neurosurgeon in the Center for Spine Health, join the Cancer Advances podcast to share insights from 20 years of a multidisciplinary spine tumor board. Learn how multidisciplinary strategies and newer technologies are improving decision-making, local control and patient outcomes.

Amy Smith, MD, Pediatric Neuro-Oncologist, joins the Cancer Advances podcast to discuss recent progress in pediatric neuro-oncology. Listen as Dr. Smith explains the advances in tumor biology that are shaping treatment decisions and shares how recent FDA approvals for pediatric low-grade gliomas and diffuse midline gliomas are improving disease control and patient outcomes.